The announcement was welcome news for those with major depressive disorder, which affects an estimated 8.3% of the adult ...

The U.S. Food and Drug Administration expanded approval for Johnson & Johnson’s nasal spray, Spravato, to allow it to be used ...

An emerging treatment for clinical depression has reached an important milestone. This week, the Food and Drug Administration ...

The following is a summary of “Intranasal racemic ketamine maintenance therapy for patients with treatment-resistant ...

New research involving ketamine continues show that having a mystical experience is key to the effectiveness of psychedelic ...

Johnson & Johnson's ketamine-derived nasal spray has been approved as a standalone treatment to fight depression for those ...

This article explores insights from Richmond-area therapists on Ketamine-Assisted Psychotherapy (KAP) and EMDR therapy, focusing on their applications in treating trauma, CPTSD, and mental health ...

The Food and Drug Administration (FDA) has approved Spravato, a nasal spray developed by Johnson & Johnson, as a standalone ...

Here's what MDs want you to know about Spravato, the latest FDA-approved standalone nasal spray for depression.

Ketamine therapy is now a mainstream prescription for treatment-resistant depression. Read more at straitstimes.com.

The U.S. Food and Drug Administration (FDA) has approved Johnson & Johnson's nasal spray, Spravato (esketamine), as the first ...

The FDA says esketamine, an antidepressant derived from the anesthetic and party drug ketamine, can now be prescribed on its ...